JOURNAL OF COMPREHENSIVE PHARMACEUTICAL AND BIOMEDICAL SCIENCES
Content Available at www.uniquepubinternational.com
(An online peer reviewed Journal) ISSN (O): 3139-7972 Published By: Unique Pub International [UPI]
Research Article
OPEN ACCESS

ROLE OF REAL WORLD EVIDENCE IN POST APPROVAL LABEL EXPANSION: A COMPARATIVE ANALYSIS OF US FDA AND INDIAN REGULATORY OPPORTUNITIES

PUPPALA BHARGAVI[1], M SWETHA[2]

[1]*Student, Department of Regulatory Affairs, Sarojini Naidu Vanitha Pharmacy Maha Vidyalaya (Co-Ed), (Affiliated to Osmania University), Hyderabad, Telangana, India.*
[2]*Associate Professor, Department of Pharmacy, Sarojini Naidu Vanitha Pharmacy Maha Vidyalaya (Co-Ed), (Affiliated to Osmania University), Hyderabad, Telangana, India.*

*Corresponding Author
M Swetha

Article History: Received: 21 Aug 2026, Revised: 24 July Oct, Accepted: 07 Nov 2026

Abstract:
Real-World Evidence (RWE), obtained from the analysis of Real-World Data (RWD) including electronic health records, insurance claims databases, patient registries, and digital health technologies, has become an essential resource for enhancing regulatory decision-making beyond conventional randomized controlled trials (RCTs). In recent years, global regulatory bodies have progressively acknowledged the capacity of real-world evidence (RWE) to produce clinically pertinent data concerning the safety, efficacy, and application of authorized pharmaceutical products in practical environments. The US Food and Drug Administration (FDA) has developed a systematic approach for incorporating Real-World Evidence (RWE) into regulatory procedures, including post-approval label modifications, supported by legislative measures like the 21st Century Cures Act and later regulatory guidance. Numerous endorsements grounded in real-world evidence have illustrated its efficacy in facilitating new indications, dosage adjustments, and broader patient demographics. On the other hand, India is in a preliminary stage in formalizing the regulatory acknowledgment of RWE. Even though the country boasts a significant and heterogeneous patient base, enhanced digitization of healthcare documentation, and an evolving pharmacovigilance system, the utilization of real-world evidence in regulatory decision-making is still restricted. This critique assesses the transforming role of RWE in the expansion of post-approval labels, scrutinizes the US FDA framework as a global reference, and discusses the potential and difficulties of implementing similar methodologies in the Indian regulatory environment. Principal aspects involve data quality assurance, governance structures, interoperability capabilities, methodological precision, patient privacy protection, and regulatory proficiency. The article highlights that strategic funding in healthcare data systems and the formulation of clear regulatory directives could allow India to use real-world evidence for expediting evidence generation, increasing patient access to treatments, and strengthening regulatory innovation. The evaluation suggests that modifying internationally acknowledged RWE principles for the Indian setting might enhance a more evidence-informed and patient-oriented regulatory system, ensuring the scientific validity and consistency of post-approval label modification determinations.

Keywords: *Real-World Evidence (RWE), Real-World Data (RWD), Post-Approval Label Expansion, US FDA, India, Regulatory Science, Drug Regulation, 21st Century Cures Act, Pharmacovigilance, Healthcare Policy.*

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License.
Copyright © 2026 Author(s) retains the copyright of this article.

INTRODUCTION

The established framework for drug discovery and regulatory verification has traditionally relied on evidence derived from randomized controlled trials (RCTs), which are viewed as the ultimate standard for assessing the safety and efficacy of therapeutic treatments. Although RCTs ensure robust internal validity via regulated study frameworks and selectively curated patient groups, they commonly face challenges regarding sample size, study length, financial implications, and relevance to larger real-world patient populations. Therefore, crucial information on a drug's effectiveness in everyday clinical use might not be accessible during the regulatory approval process. These restrictions resulted in increased interest in alternative evidence sources that can bolster regulatory decisions during a product's lifecycle [1,4].

Real-World Data (RWD) signifies healthcare-related information that is regularly collected from several sources, including electronic health records (EHRs), insurance claims databases, patient registries, wearable devices, mobile health applications, and other digital health platforms. Through the application of relevant

scientific techniques, RWD can produce Real-World Evidence (RWE), delivering insights into the effectiveness of treatments, safety outcomes, healthcare resource allocation, and patient experiences in typical clinical scenarios. Unlike standard clinical trials, real-world evidence (RWE) illustrates the heterogeneous populations, clinical practices, and healthcare contexts seen in ordinary medical treatment, thereby increasing the insight into a medicinal product's benefit-risk profile [2,8,9].

The significance of RWE in assisting several parts of medication regulation, including as pharmacovigilance, post-marketing surveillance, rare illness research, and label revisions, has been progressively acknowledged by regulatory agencies globally during the past ten years. The idea gained a lot of traction once large-scale electronic databases became more accessible and healthcare digitization progressed. Specifically, the US Food and Drug Administration (US FDA) has become a global leader in developing frameworks and regulations for the regulatory application of RWE. The FDA was prompted to assess the possibility of using RWE to assist the approval of new indications for current products and fulfilll post-approval study obligations after the 21st Century Cures Act was passed in 2016. Since then, a number of guidance publications detailing methodological and regulatory issues for the creation and evaluation of RWE have been published by the agency [5,6,7].The significance of RWE in assisting several parts of medication regulation, including as pharmacovigilance, post-marketing surveillance, rare illness research, and label revisions, has been progressively acknowledged by regulatory agencies globally during the past ten years. The idea gained a lot of popularity once large-scale electronic databases became more accessible and healthcare digitization progressed. Specifically, the US Food and Drug Administration (US FDA) has become a global leader in developing frameworks and regulations for the regulatory application of RWE. The FDA was prompted to assess the possibility of using RWE to assist the approval of new indications for current products and fulfilll post-approval study obligations after the 21st Century Cures Act was passed in 2016. Since then, a number of guidance publications detailing methodological and regulatory issues for the creation and evaluation of RWE have been published by the agency [1,11,13].

India represents a unique and quickly growing healthcare setting with tremendous potential for the application of RWE. India, being one of the major pharmaceutical markets globally, has a diverse and extensive patient demographic, a growing array of healthcare facilities, and a rising integration of digital health innovations. Programs like the Ayushman Bharat Digital Mission (ABDM), the execution of electronic health records, and the enhancement of pharmacovigilance initiatives have facilitated the gathering and application of healthcare data on an unbelievable level. Regardless these advancements, India now does not own a thorough regulatory structure specifically focused on the utilization of RWE for post-approval regulatory determinations, such as label modifications [16,18,20].

Exploring regulatory approaches that integrate RWE within the Indian context is crucial because to the growing demand for timely access to novel medications and the necessity for cost-effective evidence gathering. Indian regulators, legislators, researchers, and industry stakeholders may be able to create suitable rules that guaranty scientific rigor while utilizing the benefits of real-world data by learning from the experiences of established regulatory systems like the US FDA [14,15].

Therefore, this review article intends to investigate the significance of Real-World Evidence in post-approval label extension by rigorously assessing the regulatory structure set forth by the US FDA and scrutinizing the opportunities, problems, and future potential for its implementation in India. The review aims to pinpoint essential legislative, methodological, and infrastructural factors for incorporating RWE into India's developing drug regulatory framework and promoting evidence-based healthcare decisions.

METHODOLOGY

The United States Food and Drug Administration (US FDA) has developed a very sophisticated regulatory structure for the application of Real-World Evidence (RWE) in pharmaceutical development and post-approval regulatory assessments. The implementation of the 21st Century Cures Act in 2016 was a major achievement by instructing the FDA to assess the application of RWE in facilitating the approval of new indications and fulfilling post-approval research obligations. Subsequently, the FDA has produced extensive guideline documents outlining criteria for data significance, dependability, research design, and regulatory filing routes.

In comparison, India is still in the early phases of incorporating RWE into regulatory decision-making. While the country has made great progress in healthcare digitization and pharmacovigilance, a formal framework for RWE-based label expansion is yet to be established. The rising digital health infrastructure and increasing availability of healthcare data, however, establish a good platform for future adoption.

Table 01: Comparative Analysis of the US FDA Framework and Emerging Regulatory Opportunities in India for RWE-Based Post-Approval Label Expansion

S. No.	Parameter	US FDA Framework	Current Status in India	Opportunity for India
1	Regulatory Basis	Supported by the 21st Century Cures	No specific legislation for RWE	Introduce RWE provisions in CDSCO

		Act		regulations
2	Regulatory Guidance	Multiple FDA guidance documents available	Limited guidance on RWE use	Develop dedicated RWE guidelines
3	Acceptance of RWE	Accepted for regulatory decision-making	Limited acceptance	Formal recognition of RWE submissions
4	Post-Approval Label Expansion	RWE may support new indications and label updates	Primarily dependent on clinical trials	Create pathways for RWE-supported label changes
5	Real-World Data Sources	EHRs, claims databases, registries, wearables	Fragmented healthcare databases	Integration through ABDM
6	Electronic Health Records	Highly integrated nationwide systems	Limited adoption and standardization	Expand EHR implementation nationally
7	Patient Registries	Extensive disease-specific registries	Limited registry coverage	Establish national disease registries
8	Data Quality Standards	Robust quality assessment framework	Lack of standardized quality measures	Create national RWD quality standards
9	Data Governance	Clearly defined governance policies	Evolving governance structures	Develop transparent governance frameworks
10	Data Interoperability	High interoperability across systems	Significant interoperability gaps	Standardize health data exchange
11	Pharmacovigilance Integration	Strong integration with RWE studies	Strong PvPI program but limited RWE linkage	Link PvPI databases with clinical outcomes
12	Methodological Standards	Detailed guidance on study design and analytics	Limited methodological guidance	Publish standards for RWE study conduct
13	Industry Participation	Active pharmaceutical industry involvement	Growing industry interest	Encourage industry-sponsored RWE research
14	Academic Collaboration	Strong academia-regulator partnerships	Limited structured collaboration	Create academic-industry-regulatory networks
15	Regulatory Expertise	Dedicated RWE review teams	Limited specialized expertise	Specialized training programs for regulators
16	Digital Health Technologies	Extensive use of AI, wearables, and digital tools	Rapidly growing digital health sector	Incorporate digital health data into RWE
17	Patient-Centered Evidence	Includes patient-reported outcomes and experience data	Limited use in regulatory assessment	Promote patient-reported outcome collection
18	Review Timelines	Structured RWE review pathways	No established review mechanisms	Develop standardized review procedures
19	International Harmonization	Alignment with global regulatory standards	Limited harmonization	Adopt FDA and EMA best practices
20	Future	Mature	Emerging	Strategic

	Readiness	RWE ecosystem supporting innovation	RWE ecosystem	investment in data infrastructure and regulation

EMERGING REGULATORY OPPORTUNITIES FOR INDIA

1. Establishment of a Dedicated RWE Regulatory Framework

A formal regulatory framework designed by CDSCO would give scientific and operational guidelines for creating, analyzing, and employing RWE in regulatory decision-making. Such direction may delineate permissible data sources, analysis techniques, standards of evidence, and submission criteria [16].

2. Leveraging the Ayushman Bharat Digital Mission (ABDM)

The ABDM program is establishing a comprehensive digital healthcare framework that enables extensive gathering and amalgamation of healthcare information. This ecosystem has the potential to provide an important source of outstanding empirical data for upcoming regulatory evaluations [16].

3. Expansion of Electronic Health Records (EHRs)

Uniform implementation of electronic health records across medical facilities can enhance data thoroughness, availability, and dependability. Data collected from electronic health records can substantially aid in the assessment of post-marketing efficacy and safety [20].

4. Strengthening Pharmacovigilance-Based Evidence

The Pharmacovigilance Program of India (PvPI) provided considerable safety data. Merging these databases with clinical outcomes and therapy data may improve regulatory decision-making and assist with label adjustments [19].

5. Development of National Disease Registries

Extensive databases for cancer, diabetes, cardiovascular conditions, uncommon ailments, and infectious diseases could produce longitudinal data for assessing therapy efficacy and approving new applications [18].

6. Public-Private Partnerships

Cooperation between regulatory bodies, pharmaceutical enterprises, healthcare practitioners, technological companies, and academic organizations can promote infrastructure enhancement, data exchange, and methodological progress [16].

7. Capacity Building for Regulators

Training programs in epidemiology, biostatistics, health informatics, artificial intelligence, and pharmacoepidemiology would further improve the efficacy of Indian regulators in evaluating RWE submissions accurately [18].

8. Adoption of Global Best Practices

Acquiring insights from the FDA and EMA would enable India to formulate contextually relevant, yet globally harmonized guidelines for the evaluation and regulatory endorsement of RWE [16].

9. Integration of Artificial Intelligence and Big Data Analytics

Artificial intelligence and machine learning methodologies can enhance data processing, signal identification, predictive analytics, and the derivation of evidence from extensive real-world datasets [19].

10. Pilot RWE Programs for Label Expansion

India may initiate with pilot initiatives in therapeutic fields like oncology, rare diseases, diabetes, and cardiovascular conditions to evaluate the practicality and significance of RWE-informed regulatory choices [16].

11. Enhanced Patient-Centric Approaches

The aggregation of patient-reported outcomes and quality-of-life metrics can yield supplementary information concerning therapy efficacy and bolster more patient-centric regulatory determinations [18].

12. Creation of National RWE Centers of Excellence

Specialized centers comprising regulators, researchers, and healthcare organizations could expedite methodological research, education, and evidence production while encouraging regulatory innovation [20].

RESULTS AND DISCUSSION

The current analysis emphasizes the increasing significance of Real-World Evidence (RWE) in facilitating regulatory decisions and post-approval label modifications. An examination of the existing literature revealed that the United States Food and Drug Administration (FDA) has created a clear framework for the regulatory application of RWE, bolstered by legislative measures, methodological directives, and sophisticated healthcare data systems. The FDA's strategy has facilitated the integration of real-world data (RWD) into regulatory applications for novel indications, broader patient demographics, and post-marketing obligations, thus enhancing conventional randomized controlled trials (RCTs) [2,3].

The comparative examination uncovered significant disparities in the regulatory frameworks of the United States and India. The FDA gains advantages from well-developed electronic health record systems, extensive healthcare databases, disease registries, and established methodological standards that enable the production of trustworthy RWE. Conversely, India's regulatory framework predominantly relies on data derived from traditional clinical trials, with no formal recognition of real-world evidence for label extension determinations [5].

Notwithstanding these constraints, the results suggest that India has considerable capacity for establishing a regulatory framework based on RWE. Recent endeavors like the Ayushman Bharat Digital Mission (ABDM), the growing utilization of electronic health

records, the proliferation of digital health technologies, and the enhancement of the Pharmacovigilance Program of India (PvPI) have fostered a setting favorable for extensive real-world data gathering. These advancements establish a basis for evidence creation that may facilitate forthcoming regulatory advances [16, 18].

The examination also revealed other significant obstacles that could impede the extensive implementation of RWE in India. These encompass disjointed healthcare data systems, absence of uniform data quality standards, restricted interoperability between healthcare organizations, apprehensions about patient privacy and data management, and inadequate regulatory proficiency in assessing RWE submissions. Tackling these obstacles will be crucial for guaranteeing the dependability, authenticity, and regulatory approval of real-world evidence [20].

Moreover, the assessment indicates that the formulation of specialized regulatory directives by the Central Drugs Standard Control Organization (CDSCO) might greatly expedite the incorporation of RWE into regulatory processes. Implementing national benchmarks for data gathering, examination, and dissemination will enhance data integrity and promote increased engagement from healthcare practitioners, researchers, and the pharmaceutical sector. In a similar vein, enhancing partnerships among regulatory bodies, academic institutions, healthcare organizations, and industry participants may promote methodological progress and infrastructure enhancement.

A significant conclusion of this review is that real-world evidence should not be regarded as a substitute for randomized controlled trials, but instead as an auxiliary source of information. Although RCTs have superior internal validity, RWE offers significant insights into real-world efficacy, prolonged safety, treatment compliance, and results across varied patient demographics. The amalgamation of these evidence sources can provide more thorough and patient-focused regulatory determinations [8,10]. The results suggest that India possesses a distinctive chance to capitalize on its extensive and varied patient demographic, swiftly advancing digital health infrastructure, and increasing healthcare data assets to establish a strong RWE framework. Incorporating insights from the FDA's experience while customizing regulatory strategies to align with local healthcare contexts may promote effective post-approval label extension, foster regulatory innovation, and increase patient access to beneficial treatments. The effective incorporation of RWE into India's regulatory system could enhance evidence-driven healthcare decision-making and synchronize the nation's regulatory processes with advancing international standards [15,16,18].

CONCLUSION

Real-World Evidence (RWE) is changing the regulatory framework by offering critical insights into the safety, efficacy, and application of pharmaceutical products in standard clinical settings. The findings of this review demonstrate that the United States Food and Drug Administration (FDA) has successfully established a structured framework that supports the use of RWE in post-approval label expansion, enabling regulatory decisions that extend beyond the constraints of traditional randomized controlled trials. By incorporating high-quality Real-World Data (RWD), the FDA has shown that Real-World Evidence (RWE) can function as a reliable and scientifically sound basis for broadening indications, altering dosing guidelines, and fulfilling unmet clinical requirements. The comparative research suggests that India is now at an early stage of implementing RWE for regulatory purposes. While formal regulatory pathways for RWE-supported label expansion are still lacking, the country possesses several strategic advantages, including a large and diverse patient population, expanding healthcare infrastructure, growing electronic health record adoption, strengthening pharmacovigilance systems, and transformative initiatives such as the Ayushman Bharat Digital Mission. These advancements provide a firm foundation for the collection of high-quality real-world data and its future application in regulatory decision-making. However, various obstacles must be addressed before RWE can be effectively incorporated into India's regulatory structure. These include the need for standardized data gathering methods, greater interoperability of healthcare systems, robust data governance procedures, protection of patient privacy, and enhanced regulatory competence in analyzing RWE-based submissions. Establishing explicit national norms and methodological standards will be important to assuring the dependability, transparency, and scientific validity of evidence collected from real-world sources. India has a considerable chance to utilize global regulatory insights, especially from the FDA, as it formulates a framework specifically designed for its healthcare environment. Targeted investments in digital health frameworks, disease registries, data analysis competencies, and stakeholder partnerships can promote the prudent integration of RWE in regulatory choices. By embracing these opportunities, India may enhance regulatory efficiency, speed access to innovative therapies, support evidence-based healthcare policies, and ultimately improve patient outcomes.

In summary, RWE ought to be seen as an adjunctive resource instead of a substitute for conventional clinical trials. The amalgamation of real-world evidence with traditional clinical research could foster a more holistic, patient-focused, and flexible regulatory framework. As the healthcare landscape transforms through digital advancements, the integration of real-world evidence into post-approval label extension signifies a potential avenue for enhancing regulatory science and promoting innovation in the Indian pharmaceutical and healthcare industries.

ACKNOWLEDGEMENT
The author sincerely acknowledges Sarojini Naidu Vanitha Pharmacy Maha Vidyalayafor providing the institutional support and academic resources necessary for the completion of this work.

FUNDING
Nil

INFORM CONSENT AND ETHICAL STATEMENT
Not Applicable

CONFLICT OF INTREST
Not Declared

AUTHOR CONTRIBUTION
Both are contributed equally.

REFERENCES
1. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297.
2. United States Food and Drug Administration. Real-World Evidence [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 Nov 2]. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
3. United States Food and Drug Administration. FDA Use of Real-World Evidence in Regulatory Decision-Making [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Nov 2]. Available from: https://www.fda.gov/science-research/real-world-evidence/fda-use-real-world-evidence-regulatory-decision-making
4. Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867-868.
5. United States Food and Drug Administration. Framework for FDA's Real-World Evidence Program. Silver Spring (MD): FDA; 2018.
6. United States Food and Drug Administration. Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. Guidance for Industry. Silver Spring (MD): FDA; 2023.
7. United States Food and Drug Administration. Data Standards for Drug and Biological Product Submissions Containing Real-World Data. Guidance for Industry. Silver Spring (MD): FDA; 2023.
8. Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-865.
9. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763-1774.
10. Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness. Value Health. 2017;20(8):1003-1008.
11. Franklin JM, Patorno E. Real-world evidence in regulatory decision making: current status and future prospects. Clin Pharmacol Ther. 2022;111(1):113-121.
12. Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201-1212.
13. Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109(11):djx187.
14. ISPOR. Real-World Evidence Strategic Initiative [Internet]. Lawrenceville (NJ): International Society for Pharmacoeconomics and Outcomes Research; 2026 [cited 2026 Nov 2]. Available from: https://www.ispor.org/strategic-initiatives/topics/real-world-evidence
15. Gagne JJ, Coplan P, Davis K, Qiu H, Ryan P. Advancing patient health through regulatory-grade real-world evidence generation. Value Outcomes Spotlight. 2024;10(2):18-23.
16. National Health Authority. Ayushman Bharat Digital Mission (ABDM) [Internet]. Government of India; 2026 [cited 2026 Nov 2]. Available from: https://abdm.gov.in/
17. National Health Authority. Ayushman Bharat Digital Mission: Building India's Digital Health Ecosystem. New Delhi: Government of India; 2021.
18. Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India (PvPI) [Internet]. Ghaziabad: Ministry of Health and Family Welfare; 2026 [cited 2026 Nov 2].
19. Indian Pharmacopoeia Commission. Pharmacovigilance Guidelines for Stakeholders. Ghaziabad: NCC-PvPI; 2024.
20. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance programme of India: recent developments and future perspectives. Indian J Pharmacol. 2016;48(6):624-628.
21. Gogtay NJ, Ravi R, Thatte UM. Regulatory requirements for clinical trials in India and opportunities for real-world evidence generation. Perspect Clin Res. 2017;8(1):1-4.
22. Gupta YK, Ramachandran SS. Strengthening pharmacovigilance and regulatory sciences in India. Indian J Pharmacol. 2018;50(1):S1-S5.